Webinar: Detection of therapeutically targetable mutations in NSCLC: Is there a one size fits all cell free DNA test?
Detecting tumor-specific mutations using circulating cell free DNA analysis has diagnostic and therapeutic applications.
Leading experts, Prof. Ed Schuuring and Dr. Darryl Irwin, will discuss the clinical applications of circulating cell free DNA (ccfDNA) in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors or immune checkpoint inhibitors.
- Utility of circulating tumor DNA (ctDNA) as a minimally invasive molecular tool to guide treatment decisions and disease monitoring, especially when no appropriate tumor tissue biopsy is available.
- Characteristics of a suitable diagnostic-grade platform required for the detection of tumor-specific mutations with high sensitivity in ccfDNA.
- Review of a liquid biopsy lung panel for the detection of the most common predictive markers in comparison to other circulating tumor DNA (ctDNA) detection assays for NSCLC.
Ed Schuuring, PhD
Professor of Molecular Oncological Pathology at University Medical Center Groningen, Netherlands
Darryl Irwin, PhD
Vice President of Scientific Affairs at Agena Bioscience, Queensland, Australia
Moderator: Bob McGonnagle, Publisher, CAP TODAY
Recorded on October 13, 2021
Learn more about our liquid biopsy solutions.